Brief: Nicox Accelerates Topline Results From NCX 470 Mont Blanc Phase 3 Glaucoma Trial To November 2022
03/06/2022 06:32
June 3 (Reuters) - Nicox SA NCOX.PA :
* REG-NICOX ACCELERATES TOPLINE RESULTS FROM NCX 470 MONT
BLANC
PHASE 3 GLAUCOMA TRIAL TO NOVEMBER 2022
* PHASE 3 MONT BLANC CLINICAL TRIAL APPROACHES STUDY
COMPLETION
WITH SCREENING CLOSED
* PHASE 3 RESULTS WILL BE A KEY MILESTONE FOR COMPANY
* NCX 470 0.065% HAS ALREADY DEMONSTRATED A STATISTICALLY
SIGNIFICANT GREATER REDUCTION OF INTRAOCULAR PRESSURE
* REDUCTION AS COMPARED TO LATANOPROST 0.005% IN A PHASE 2
TRIAL
AND IS BEING EVALUATED IN PHASE 3 AT A HIGHER CONCENTRATION THAN
WAS TESTED IN PHASE 2
* DENALI TOPLINE RESULTS ARE EXPECTED AFTER 2023 AND COMPANY
WILL
ANNOUNCE A NEW DATE FOR AVAILABILITY OF RESULTS WHEN WE HAVE A
MORE FIRM ESTIMATE OF OVERALL TIMELINES OF TRIAL
* IN ADDITION, NCX 470 RESULTS ON RETINAL CELL PROTECTION IN
ANIMAL MODELS RECENTLY PRESENTED AT ARVO 2022 ALSO OPEN WAY TO
FURTHER DIFFERENTIATED PRODUCT PROFILE -CEO
Source text for Eikon: ID:nGNE6pn7rQ
Further company coverage: NCOX.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))